Radiogenomics is an emerging field that integrates “Radiomics” and “Genomics”. In the current study, we aimed to predict the genetic information of pancreatic tumours in a simple, inexpensive, and non-invasive manner, using cancer imaging analysis and radiogenomics. We focused on p53 mutations, which are highly implicated in pancreatic ductal adenocarcinoma (PDAC), and PD-L1, a biomarker for immune checkpoint inhibitor-based therapies.
Overall, 107 patients diagnosed with PDAC were retrospectively examined. The relationship between p53 mutations as well as PD-L1 abnormal expression and clinicopathological factors was investigated using immunohistochemistry. Imaging features (IFs) were extracted from CT scans and were used to create prediction models of p53 and PD-L1 status.
We found that p53 and PD-L1 are significant independent prognostic factors (P = 0.008, 0.013, respectively). The area under the curve for p53 and PD-L1 predictive models was 0.795 and 0.683, respectively. Radiogenomics-predicted p53 mutations were significantly associated with poor prognosis (P = 0.015), whereas the predicted abnormal expression of PD-L1 was not significant (P = 0.096).
Radiogenomics could predict p53 mutations and in turn the prognosis of PDAC patients. Hence, prediction of genetic information using radiogenomic analysis may aid in the development of precision medicine.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Spath, C., Nitsche, U., Muller, T., Michalski, C., Erkan, M., Kong, B. et al. Strategies to improve the outcome in locally advanced pancreatic cancer. Minerva Chir. 70, 97–106 (2015).
Waddell, N., Pajic, M., Patch, A. M., Chang, D. K., Kassahn, K. S., Bailey, P. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
Kamisawa, T., Wood, L. D., Itoi, T. & Takaori, K. Pancreatic cancer. Lancet (Lond., Engl.) 388, 73–85 (2016).
Oshima, M., Okano, K., Muraki, S., Haba, R., Maeba, T., Suzuki, Y. et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann. Surg. 258, 336–346 (2013).
Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Gao, H. L., Liu, L., Qi, Z. H., Xu, H. X., Wang, W. Q., Wu, C. T. et al. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat. Dis. Int. 17, 95–100 (2018).
Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
Herskind, C., Talbot, C. J., Kerns, S. L., Veldwijk, M. R., Rosenstein, B. S. & West, C. M. Radiogenomics: a systems biology approach to understanding genetic risk factors for radiotherapy toxicity? Cancer Lett. 382, 95–109 (2016).
Woodard, G. A., Ray, K. M., Joe, B. N. & Price, E. R. Qualitative radiogenomics: association between oncotype DX Test recurrence score and BI-RADS mammographic and breast MR imaging features. Radiology 286, 60–70 (2018).
Zhou, M., Leung, A., Echegaray, S., Gentles, A., Shrager, J. B., Jensen, K. C. et al. Non-small cell lung cancer radiogenomics map identifies relationships between molecular and imaging phenotypes with prognostic implications. Radiology 286, 307–315 (2018).
Kickingereder, P., Bonekamp, D., Nowosielski, M., Kratz, A., Sill, M., Burth, S. et al. Radiogenomics of glioblastoma: machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology 281, 907–918 (2016).
Eilaghi, A., Baig, S., Zhang, Y., Zhang, J., Karanicolas, P., Gallinger, S. et al. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma—a quantitative analysis. BMC Med. Imaging 17, 38 (2017).
Sun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R. et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 19, 1180–1191 (2018).
Attiyeh, M. A., Chakraborty, J., McIntyre, C. A., Kappagantula, R., Chou, Y., Askan, G. et al. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Abdom. Radiol. 44, 3148–3157 (2019).
Attiyeh, M. A., Chakraborty, J., Doussot, A., Langdon-Embry, L., Mainarich, S., Gonen, M. et al. Survival prediction in pancreatic ductal adenocarcinoma by quantitative computed tomography image analysis. Ann. surgical Oncol. 25, 1034–1042 (2018).
Kobel, M., Ronnett, B. M., Singh, N., Soslow, R. A., Gilks, C. B. & McCluggage, W. G. Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility. Int. J. Gynecol. Pathol. 38, S123–S131 (2019).
van Griethuysen, J. J. M., Fedorov, A., Parmar, C., Hosny, A., Aucoin, N., Narayan, V. et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 77, e104–e107 (2017).
Feldser, D. M., Kostova, K. K., Winslow, M. M., Taylor, S. E., Cashman, C., Whittaker, C. A. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010).
Furukawa, H., Makino, T., Yamasaki, M., Tanaka, K., Miyazaki, Y., Takahashi, T. et al. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. Cancer Sci. 109, 412–421 (2018).
Saha, M. N., Jiang, H., Yang, Y., Reece, D. & Chang, H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol. Cancer Ther. 12, 2331–2341 (2013).
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M. & Poulsen, H. S. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 17, 2830–2841 (2011).
Liang, Y., Besch-Williford, C. & Hyder, S. M. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int. J. Oncol. 35, 1015–1023 (2009).
Li, X. L., Zhou, J., Chan, Z. L., Chooi, J. Y., Chen, Z. R. & Chng, W. J. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget 6, 36689–36699 (2015).
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M. et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J. Exp. Clin. Cancer Res. 38, 397 (2019).
Schlitter, A. M., Segler, A., Steiger, K., Michalski, C. W., Jager, C., Konukiewitz, B. et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci. Rep. 7, 41064 (2017).
Vennin, C., Melenec, P., Rouet, R., Nobis, M., Cazet, A. S., Murphy, K. J. et al. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nat. Commun. 10, 3637 (2019).
Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304–317 (2014).
Murnyak, B. & Hortobagyi, T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget 7, 64910–64920 (2016).
Kaserer, K., Schmaus, J., Bethge, U., Migschitz, B., Fasching, S., Walch, A. et al. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J. Pathol. 190, 450–456 (2000).
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, Ie. M. et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 24, 1248–1253 (2011).
Hodgson, A., Xu, B. & Downes, M. R. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 71, 296–304 (2017).
Alsner, J., Jensen, V., Kyndi, M., Offersen, B. V., Vu, P., Borresen-Dale, A. L. et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 47, 600–607 (2008).
Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 75, 2139–2145 (2015).
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
Hectors, S. J., Wagner, M., Bane, O., Besa, C., Lewis, S., Remark, R. et al. Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci. Rep. 7, 2452 (2017).
Taguchi, N., Oda, S., Yokota, Y., Yamamura, S., Imuta, M., Tsuchigame, T. et al. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. Eur. J. Radiol. 118, 38–43 (2019).
Hoshino, I., Yokota, H., Ishige, F., Iwatate, Y., Takeshita, N., Nagase, H. et al. Radiogenomics predicts the expression of microRNA-1246 in the serum of esophageal cancer patients. Sci. Rep. 10, 2532 (2020).
Hutchings, D., Waters, K. M., Weiss, M. J., Wolfgang, C. L., Makary, M. A., He, J. et al. Cancerization of the pancreatic ducts: demonstration of a common and under-recognized process using immunolabeling of paired duct lesions and invasive pancreatic ductal adenocarcinoma for p53 and Smad4 expression. Am. J. surgical Pathol. 42, 1556–1561 (2018).
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15–16 (1992).
Ethics approval and consent to participate
This study was approved by the Chiba Cancer Center Review Board (H29-006). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all patients in this study.
Consent to publish
Written informed consent was obtained from the patients for publication of this study and accompanying clinicopathological data.
The data that support the findings of this study are available from the corresponding author upon reasonable request.
The authors declare no competing interests.
Funding information is not applicable.
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Iwatate, Y., Hoshino, I., Yokota, H. et al. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. Br J Cancer 123, 1253–1261 (2020). https://doi.org/10.1038/s41416-020-0997-1
Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends
The AAPS Journal (2021)
Radiogenomics of gastroenterological cancer: The dawn of personalized medicine with artificial intelligence‐based image analysis
Annals of Gastroenterological Surgery (2021)